[1]
|
Arber, D.A., Orazi, A., Hasserjian, R., et al. (2016) The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia. Blood, 127, 2391-2405. https://doi.org/10.1182/blood-2016-03-643544
|
[2]
|
Stuckey, R. and Gómez-Casares, M.T. (2021) Recent Ad-vances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera. International Journal of Molecular Sciences, 22, 5042.
https://doi.org/10.3390/ijms22095042
|
[3]
|
Jia, R. and Kralovics, R. (2020) Progress in Elucidation of Molecular Pathophysiology of Myeloproliferative Neoplasms and Its Application to Therapeutic Decisions. International Journal of Hematology, 111, 182-191.
https://doi.org/10.1007/s12185-019-02778-9
|
[4]
|
Takenaka, K. (2020) Progress in Elucidation of Molecular Path-ophysiology and Its Application in Therapeutic Decision-Making for Myeloproliferative Neoplasms. International Jour-nal of Hematology, 111, 180-181.
https://doi.org/10.1007/s12185-019-02812-w
|
[5]
|
Szybinski, J. and Meyer, S.C. (2021) Genetics of Myeloprolif-erative Neoplasms. Hematology/Oncology Clinics of North America, 35, 217-236. https://doi.org/10.1016/j.hoc.2020.12.002
|
[6]
|
Passamonti, F., Elena, C., Schnittger, S., et al. (2011) Molecular and Clinical Features of the Myeloproliferative Neoplasm Associated with JAK2 Exon 12 Mutations. Blood, 117, 2813-2816.
https://doi.org/10.1182/blood-2010-11-316810
|
[7]
|
Scott, L.M., Tong, W., Levine, R.L., et al. (2007) JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. The New England Journal of Medicine, 356, 459-468. https://doi.org/10.1056/NEJMoa065202
|
[8]
|
McNally, R., Toms, A.V. and Eck, M.J. (2016) Crystal Structure of the FERM-SH2 Module of Human Jak2. PLOS ONE, 11, e0156218. https://doi.org/10.1371/journal.pone.0156218
|
[9]
|
Raivola, J., Haikarainen, T., Abraham, B.G. and Silvennoinen, O. (2021) Janus Kinases in Leukemia. Cancers, 13, 800.
https://doi.org/10.3390/cancers13040800
|
[10]
|
Bharadwaj, U., Kasembeli, M.M., Robinson, P. and Tweardy, D.J. (2020) Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Infammation, Fbrosis, and Cancer: Rationale, Progress, and Caution. Pharmacological Reviews, 72, 486-526. https://doi.org/10.1124/pr.119.018440
|
[11]
|
Dusa, A., Mouton, C., Pecquet, C., et al. (2010) JAK2 V617F Consti-tutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors. PLOS ONE, 5, e11157.
https://doi.org/10.1371/journal.pone.0011157
|
[12]
|
Wingelhofer, B., Neubauer, H.A., Valent, P., et al. (2018) Im-plications of STAT3 and STAT5 Signaling on Gene Regulation and Chromatin Remodeling in Hematopoietic Cancer. Leukemia, 32, 1713-1726.
https://doi.org/10.1038/s41375-018-0117-x
|
[13]
|
Vainchenker, W. and Kralovics, R. (2017) Genetic Basis and Mo-lecular Pathophysiology of Classical Myeloproliferative Neoplasms. Blood, 129, 667-679. https://doi.org/10.1182/blood-2016-10-695940
|
[14]
|
(2020) Online Mendelian Iinheritance in Man: An Online Cat-alog of Human Genes and Genetic Disorders. Johns Hopkins University, Baltimore.
|
[15]
|
Ding, J., Komatsu, H., Wakita, A., et al. (2004) Familial Essential Thrombocythemia Associated with a Dominant- Positive Activating Mutation of the c-MPL Gene, Which Encodes for the Receptor for Thrombopoietin. Blood, 103, 4198-4200. https://doi.org/10.1182/blood-2003-10-3471
|
[16]
|
Staerk, J., Lacout, C., Sato, T., et al. (2006) An Amphipathic Motif at the Transmembrane-Cytoplasmic Junction Prevents Autonomous Activation of the Thrombopoietin Receptor. Blood, 107, 1864-1871.
https://doi.org/10.1182/blood-2005-06-2600
|
[17]
|
Mead, A.J. and Mullally, A. (2017) Myeloproliferative Neoplasm Stem Cells. Blood, 129, 1607-1616.
https://doi.org/10.1182/blood-2016-10-696005
|
[18]
|
Tiedt, R., Coers, J., Ziegler, S., Wiestner, A., Hao-Shen, H., Bornmann, C., Schenkel, J., Karakhanova, S., De Sauvage, F.J., Jackson, C.W., et al. (2009) Pronounced Thrombocyto-sis in Transgenic Mice Expressing Reduced Levels of Mpl in Platelets and Terminally Differentiated Megakaryocytes. Blood, 113, 1768-1777.
https://doi.org/10.1182/blood-2008-03-146084
|
[19]
|
Lannutti, B.J., Epp, A., Roy, J., Chen, J. and Josephson, N.C. (2009) Incomplete Restoration of Mpl Expression in the mpl/Mouse Produces Partial Correction of the Stem Cell-Repopulating Defect and Paradoxical Thrombocytosis. Blood, 113, 1778-1785. https://doi.org/10.1182/blood-2007-11-124859
|
[20]
|
Prins, D., Arias, C.G., Klampflfl, T., Grinfeld, J. and Green, A.R. (2020) Mutant Calreticulin in the Myeloproliferative Neoplasms. HemaSphere, 4, e333. https://doi.org/10.1097/HS9.0000000000000333
|
[21]
|
Klampfl, T., Gisslinger, H., Harutyunyan, A.S., et al. (2013) Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. The New England Journal of Medicine, 369, 2379-2390. https://doi.org/10.1056/NEJMoa1311347
|
[22]
|
Rumi, E. and Cazzola, M. (2017) Diagnosis, Risk Strat-ification, and Response Evaluation in Classical Myeloproliferative Neoplasms. Blood, 129, 680-692. https://doi.org/10.1182/blood-2016-10-695957
|
[23]
|
Rumi, E., Pietra, D., Ferretti, V., et al. (2014) JAK2 or CALR Mutation Status Defines Subtypes of Essential Thrombocythemia with Substantially Different Clinical Course and Out-comes. Blood, 123, 1544-1551.
https://doi.org/10.1182/blood-2013-11-539098
|
[24]
|
Rumi, E., Pietra, D., Pascutto, C., et al. (2014) Clinical Effect of Driver Mutations of JAK2, CALR, or MPL in Primary Myelofibrosis. Blood, 124, 1062-1069. https://doi.org/10.1182/blood-2014-05-578435
|
[25]
|
Tefferi, A., Lasho, T.L., Finke, C.M., et al. (2014) CALR vs JAK2 vs MPL-Mutated or Triple-Negative Myelofibrosis: Clinical, Cytogenetic and Molecular Comparisons. Leukemia, 28, 1472-1477. https://doi.org/10.1038/leu.2014.3
|
[26]
|
Nangalia, J., Massie, C.E., Baxter, E.J., et al. (2013) So-matic CALR Mutations in Myeloproliferative Neoplasm with Nonmutated JAK2. The New England Journal of Medicine, 369, 2391-2405. https://doi.org/10.1056/NEJMoa1312542
|
[27]
|
How, J., Hobbs, G.S. and Mullally, A. (2019) Mutant Calreticulin in Myeloproliferative Neoplasms. Blood, 134, 2242- 2248. https://doi.org/10.1182/blood.2019000622
|
[28]
|
Pietra, D., Rumi, E., Ferretti, V.V., Di Buduo, C.A., Milanesi, C., Cavalloni, C., Sant’Antonio, E., Abbonante, V., Moccia, F., Casetti, I.C., et al. (2016) Faculty Opinions Recommenda-tion of Differential Clinical Effects of Different Mutation Subtypes in CALR-Mutant Myeloproliferative Neoplasms. Leukemia, 30, 431-438.
https://doi.org/10.1038/leu.2015.277
|
[29]
|
Masubuchi, N., Araki, M., Yang, Y., Hayashi, E., Imai, M., Edahiro, Y., Hironaka, Y., Mizukami, Y., Kihara, Y., Takei, H., et al. (2020) Mutant Calreticulin Interacts with MPL in the Secretion Pathway for Activation on the Cell Surface. Leukemia, 34, 499-509. https://doi.org/10.1038/s41375-019-0564-z
|
[30]
|
Cabagnols, X., Favale, F., Pasquier, F., et al. (2016) Presence of Atypical Thrombopoietin Receptor (MPL) Mutations in Triple-Negative Essential Thrombocythemia Patients. Blood, 127, 333-342.
https://doi.org/10.1182/blood-2015-07-661983
|
[31]
|
Milosevic Feenstra, J.D., Nivarthi, H., Gisslinger, H., et al. (2016) Whole-Exome Sequencing Identifies Novel MPL and JAK2 Mutations in Triple-Negative Myeloproliferative Neoplasms. Blood, 127, 325-332.
https://doi.org/10.1182/blood-2015-07-661835
|
[32]
|
Michail, O., McCallion, P., McGimpsey, J., et al. (2020) Mu-tational Profling in Suspected Triple-Negative Essential Thrombocythaemia Using Targeted Next-Generation Sequencing in a Real-World Cohort. Journal of Clinical Pathology, 74, 808-811. https://doi.org/10.1136/jclinpath-2020-206570
|
[33]
|
Tefferi, A., Lasho, T.L., Finke, C., Belachew, A.A., Wassie, E.A., Ketterling, R.P., Hanson, C.A. and Pardani, A. (2014) Type 1 vs. Type 2 Calreticulin Mutations in Primary Myelo-fibrosis: Differences in Phenotype and Prognostic Impact. Leukemia, 28, 1568-1570. https://doi.org/10.1038/leu.2014.83
|
[34]
|
Lee, J., Godfrey, A.L. and Nangalia, J. (2020) Genomic Heterogeneity in Myeloproliferative Neoplasms and Applications to Clinical Practice. Blood Reviews, 42, Article ID: 100708. https://doi.org/10.1016/j.blre.2020.100708
|
[35]
|
Marneth, A.E. and Mullally, A. (2020) The Molecular Genetics of Myeloproliferative Neoplasms. Cold Spring Harbor Perspectives in Medicine, 10, a034876. https://doi.org/10.1101/cshperspect.a034876
|
[36]
|
Morsia, E., Torre, E., Poloni, A., Olivieri, A. and Rupoli, S. (2022) Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications. International Journal of Molecular Sciences, 23, 4573. https://doi.org/10.3390/ijms23094573
|
[37]
|
Chachoua, I., Pecquet, C., El-Khoury, M., Nivarthi, H., Albu, R.I., Marty, C., Gryshkova, V., Defour, J.P., Vertenoeil, G., Ngo, A., et al. (2016) Thrombopoietin Receptor Activation by Myeloproliferative Neoplasm Associated Calreticulin Mutants. Blood, 127, 1325-1335. https://doi.org/10.1182/blood-2015-11-681932
|
[38]
|
Brkic, S. and Meyer, S.C. (2021) Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms. Hemasphere, 5, e516. https://doi.org/10.1097/HS9.0000000000000516
|
[39]
|
Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Nieder-wieser, D., Or, R., Szer, J., Wagner, E.M., Zuckerman, T., Mahuzier, B., et al. (2020) Ruxolitinib for Glucocorti-coid-Refractory Acute Graft-versus-Host Disease. The New England Journal of Medicine, 382, 1800-1810. https://doi.org/10.1056/NEJMoa1917635
|
[40]
|
Zeiser, R., Polverelli, N., Ram, R., Hashmi, S.K., Chakraverty, R., Middeke, J.M., Musso, M., Giebel, S., Uzay, A., Langmuir, P., et al. (2021) Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. The New England Journal of Medicine, 385, 228-238. https://doi.org/10.1056/NEJMoa2033122
|
[41]
|
Harrison, C., Kiladjian, J., Al-Ali, H., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., et al. (2012) JAK Inhibition with Ruxolitinib ver-sus Best Available Therapy for Myelofibrosis. The New England Journal of Medicine, 366, 787-798. https://doi.org/10.1056/NEJMoa1110556
|
[42]
|
Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., Di-Persio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., et al. (2012) A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. The New England Journal of Medicine, 366, 799-807. https://doi.org/10.1056/NEJMoa1110557
|
[43]
|
Vannucchi, A.M., Kiladjian, J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C.N., Pane, F., Zachee, P., Mesa, R., et al. (2015) Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. The New England Journal of Medicine, 372, 426-435. https://doi.org/10.1056/NEJMoa1409002
|
[44]
|
Verstovsek, S., Vannucchi, A.M., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C.N., Pane, F., Zachee, P., Kirito, K., et al. (2016) Ruxolitinib versus Best Availa-ble Therapy in Patients with Polycythemia Vera: 80-Week Follow-Up from the RESPONSE Trial. Haematologica, 101, 821-829.
https://doi.org/10.3324/haematol.2016.143644
|
[45]
|
Passamonti, F., Griesshammer, M., Palandri, F., Egyed, M., Benevolo, G., Devos, T., Callum, J., Vannucchi, A.M., Sivgin, S., Bensasson, C., et al. (2017) Ruxolitinib for the Treatment of Inadequately Controlled Polycythaemia Vera without Splenomegaly (RESPONSE-2): A Randomised, Open-Label, Phase 3b Study. The Lancet Oncology, 18, 88-99.
https://doi.org/10.1016/S1470-2045(16)30558-7
|
[46]
|
Griesshammer, M., Saydam, G., Palandri, F., Benevolo, G., Egyed, M., Callum, J., Devos, T., Sivgin, S., Guglielmelli, P., Bensasson, C., et al. (2018) Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 80-Week Follow-Up from the RESPONSE-2 Trial. Annals of Hematology, 97, 1591-1600.
https://doi.org/10.1007/s00277-018-3365-y
|
[47]
|
Deininger, M., Radich, J., Burn, T.C., Huber, R., Paranagama, D. and Verstovsek, S. (2015) The Effect of Long-Term Ruxolitinib Treatment on JAK2p.V617F Allele Burden in Patients with Myelofibrosis. Blood, 126, 1551-1554.
https://doi.org/10.1182/blood-2015-03-635235
|
[48]
|
Talpaz, M. and Kiladjian, J.-J. (2021) Fedratinib, a Newly Ap-proved Treatment for Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis. Leukemia, 35, 1-17. https://doi.org/10.1038/s41375-020-0954-2
|
[49]
|
Mullally, A., Hood, J., Harrison, C. and Mesa, R. (2020) Fedrat-inib in Myelofibrosis. Blood Advances, 4, 1792-1800.
https://doi.org/10.1182/bloodadvances.2019000954
|
[50]
|
Schönberg, K., Rudolph, J., Vonnahme, M., Yajnana-rayana, S.P., Cornez, I., Hejazi, M., Manser, A.R., Uhrberg, M., Verbeek, W., Koschmieder, S., et al. (2015) JAK Inhi-bition Impairs NK Cell Function in Myeloproliferative Neoplasms. Cancer Research, 75, 2187-2199. https://doi.org/10.1158/0008-5472.CAN-14-3198
|
[51]
|
Mesa, R.A., Kiladjian, J.-J., Catalano, J.V., Devos, T., Egyed, M., Hellmann, A., McLornan, D., Shimoda, K., Winton, E.F., Deng, W., et al. (2017) SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis. Jour-nal of Clinical Oncology, 35, 3844-3850.
https://doi.org/10.1200/JCO.2017.73.4418
|
[52]
|
Patel, A.A. and Odenike, O. (2020) The Next Generation of JAK Inhibitors: An Update on Fedratinib, Momelotonib, and Pacritinib. Current Hematologic Malignancy Reports, 15, 409-418. https://doi.org/10.1007/s11899-020-00596-z
|
[53]
|
Harrison, C., Vannucchi, A.M., Platzbecker, U., Cer-vantes, F., Gupta, V., Lavie, D., Passamonti, F., Winton, E.F., Dong, H., Kawashima, J., et al. (2018) Momelotinib ver-sus Best Available Therapy in Patients with Myelofibrosis Previously Treated with Ruxolitinib (SIMPLIFY 2): A Ran-domised, Open-Label, Phase 3 Trial. The Lancet Haematology, 5, e73-e81. https://doi.org/10.1016/S2352-3026(17)30237-5
|
[54]
|
Singer, J.W., Al-Fayoumi, S., Ma, H., Komrokji, R.S., Mesa, R. and Verstovsek, S. (2016) Comprehensive Kinase Profile of Pacritinib, a Nonmyelosuppressive Janus Kinase 2 Inhib-itor. Journal of Experimental Pharmacology, 8, 11-19.
https://doi.org/10.2147/JEP.S110702
|
[55]
|
Mesa, R.A., Vannucchi, A.M., Mead, A.J., Egyed, M., Szoke, A., Su-vorov, A., Jakucs, J., Perkins, A., Prasad, R., Mayer, J., et al. (2017) Pacritinib versus Best Available Therapy for the Treatment of Myelofibrosis Irrespective of Baseline Cytopenias (PERSIST-1): An International, Randomised, Phase 3 Trial. The Lancet Haematology, 4, e225- e236. https://doi.org/10.1016/S2352-3026(17)30027-3
|
[56]
|
Harrison, C.N., Vannucchi, A.M., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Knoops, L., Cervantes, F., Jones, M.M., Sun, K., McQuitty, M., et al. (2016) Long-Term Findings from COMFORT-II, a Phase 3 Study of Ruxolitinib vs Best Available Therapy for Myelofibrosis. Leukemia, 30, 1701-1707. https://doi.org/10.1038/leu.2016.148
|
[57]
|
Kiladjian, J.J., Zachee, P., Hino, M., Pane, F., Masszi, T., Harrison, C.N., Mesa, R., Miller, C.B., Passamonti, F., Durrant, S., et al. (2020) Long-Term Efficacy and Safety of Ruxolitinib versus Best Available Therapy in Polycythaemia Vera (RESPONSE): 5-Year Follow up of a Phase 3 Study. The Lancet Haematology, 7, e226-e237.
https://doi.org/10.1016/S2352-3026(19)30207-8
|
[58]
|
Luo, Q., Xiao, Z. and Peng, L. (2021) Effects of Ruxolitinib on Infection in Patients with Myeloproliferative Neoplasm: A Meta-Analysis. Hematology, 26, 663-669. https://doi.org/10.1080/16078454.2021.1967256
|
[59]
|
Sadjadian, P., Wille, K., Griesshammer, M., Sadjadian, P., Wille, K. and Griesshammer, M. (2020) Ruxolitinib-Asso- ciated Infections in Polycythemia Vera: Review of the Litera-ture, Clinical Significance, and Recommendations. Cancers, 12, 3132. https://doi.org/10.3390/cancers12113132
|
[60]
|
Khalid, F., Damlaj, M., Al Zahrani, M., Abuelgasim, K.A. and Gma-ti, G.E. (2021) Reactivation of Tuberculosis Following Ruxolitinib Therapy for Primary Myelofibrosis: Case Series and Literature Review. Hematology/Oncology and Stem Cell Therapy, 14, 252-256. https://doi.org/10.1016/j.hemonc.2020.02.003
|
[61]
|
Duan, M.-H., Cao, X.-X., Chang, L. and Zhou, D.-B. (2021) Risk of Hepatitis B Virus Reactivation Following Ruxolitinib Treatment in Patients with Myeloproliferative Neoplasms. Hematology, 26, 460-464.
https://doi.org/10.1080/16078454.2021.1945234
|
[62]
|
Devos, T., Selleslag, D., Granacher, N., Havelange, V. and Benghiat, F.S. (2022) Updated Recommendations on the Use of Ruxolitinib for the Treatment of Myelofibrosis. Hema-tology, 27, 23-31.
https://doi.org/10.1080/16078454.2021.2009645
|
[63]
|
Barraco, F., Greil, R., Herbrecht, R., Schmidt, B., Reiter, A., Willenbacher, W., Raymakers, R., Liersch, R., Wroclawska, M., Pack, R., et al. (2020) Real-World Non-Interventional Long-Term Post-Authorisation Safety Study of Ruxolitinib in Myelofibrosis. British Journal of Haematology, 191, 764-774. https://doi.org/10.1111/bjh.16729
|
[64]
|
Truong, B., Zhang, Y., Fahl, S., Cai, K.Q., Martinez, E., Al-Saleem, E.D., Gong, Y., Liebermann, D., Soboloff, J., Dunbrack, R., et al. (2021) ERK2 Substrate Binding Domains Perform Opposing Roles in Pathogenesis of a JAK2V617F- Driven Myeloproliferative Neoplasm. Blood, 138, 2547. https://doi.org/10.1182/blood-2021-152063
|